Previous research has shown gender differences with respect to entry into medication treatment of substance use disorders (SUDs), yet few have examined gender differences among participants consented to be treated with extended-release naltrexone (XR-NTX). Understanding gender differences is critical to developing interventions to overcome barriers to initiation of and retention on medication treatment for SUDs.
Methods
Data from two double-blind placebo-controlled trials of XR-NTX among persons with HIV and alcohol or opioid use disorders leaving the criminal justice system (CJS) were analyzed for gender differences among clinical characteristics, mental health, drug use severity, and other domains. The study that recruited persons with alcohol use disorder (AUD) was conducted from September 2010–February 2016 at two sites in Connecticut (CT), and the opioid use disorder (OUD) study was conducted from September 2010–March 2016 at three sites in CT and one site in Massachusetts.
Results
Baseline data were analyzed from 193 participants consented to be randomized to XR-NTX or placebo; 40 women and 153 men. Women were younger, had worse mental health severity, and were more likely to be diagnosed with cocaine use disorder. There were no statistical differences between men and women in the prescription of antiretroviral therapy (ART) or ART adherence.
Conclusions
Women had greater mental health severity and a higher prevalence of cocaine use as compared to men, both of which are known to be barriers to engagement and retention on medication treatment for alcohol and opioid use disorders. For women with CJS involvement and living with HIV and SUDs, understanding factors that may affect initiation and retention on medication treatment of SUDs are necessary to improve treatment outcomes in women.
Des JarlaisDC, FeelemyerJP, ModiSN, ArastehK, HaganH.Are females who inject drugs at higher risk for HIV infection than males who inject drugs: an international systematic review of high seroprevalence areas. Drug Alcohol Depend. 2012;124(1–2):95–107.
2.
MeyerJP, SpringerSA, AlticeFL.Substance abuse, violence, and HIV in women: a literature review of the syndemic. J Womens Health. 2011;20(7):991–1006.
3.
GreenfieldSF, BrooksAJ, GordonSM, . Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend. 2007;86(1):1–21.
4.
McHughRK, DevitoEE, DoddD, . Gender differences in a clinical trial for prescription opioid dependence. J Subst Abuse Treat. 2013;45(1):38–43.
5.
McHughRK, VotawVR, SugarmanDE, GreenfieldSF.Sex and gender differences in substance use disorders. Clin Psychol Rev. 2018;66:12–23.
6.
BackSE, PayneRL, WahlquistAH, . Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse.2011;37(5):313–323.
7.
Hernandez-AvilaCA, RounsavilleBJ, KranzlerHR.Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 2004;74(3):265–272.
8.
CampbellANC, Barbosa-LeikerC, Hatch-MailletteM, . Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. Am J Addict. 2018;27(6):465–470.
9.
LeoneB, Di NicolaM, MocciaL, . Gender-related psychopathology in opioid use disorder: results from a representative sample of Italian addiction services. Addict Behav. 2017;71:107–110.
10.
GrellaCE, KarnoMP, WardaUS, NivN, MooreAA.Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav. 2009;34(6–7):498–504.
11.
AljassemK, RaboudJM, HartTA, . Gender Differences in severity and correlates of depression symptoms in people living with HIV in Ontario, Canada. J Int Assoc Provid AIDS Care. 2016;15(1):23–35.
12.
SuhJJ, PettinatiHM, KampmanKM, O'BrienCP.Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. Am J Addict. 2008;17(6):463–468.
MazureCM, FiellinDA.Women and opioids: something different is happening here. The Lancet.2018;392(10141):9–11.
15.
MeyerJP, IsaacsK, El-ShahawyO, BurlewAK, WechsbergW.Research on women with substance use disorders: reviewing progress and developing a research and implementation roadmap. Drug Alcohol Depend. 2019;197:158–163.
SpringerSA, Di PaolaA, AzarMM, . Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial. J Acquir Immune Defic Syndr.2018;78(1):43–53.
18.
Di PaolaA, LincolnT, SkiestDJ, DesabraisM, AlticeFL, SpringerSA.Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemp Clin Trials. 2014;39(2):256–268.
19.
SpringerSA, AlticeFL, HermeM, Di PaolaA.Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemp Clin Trials. 2014;37(2):209–218.
20.
SpringerSA, Di PaolaA, AzarMM, BarbourR, KrishnanA, AlticeFL.Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug Alcohol Depend. 2017;174:158–170.
21.
SpringerSA, Di PaolaA, BarbourR, AzarMM, AlticeFL.Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: results from a double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr.2018;79(1):92–100.
22.
SheehanDV, LecrubierY, SheehanKH, . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry.1998;59 (Suppl 20):22–33. quiz 4–57.
23.
WangJ, KellyBC, BoothBM, FalckRS, LeukefeldC, CarlsonRG.Examining factorial structure and measurement invariance of the Brief Symptom Inventory (BSI)-18 among drug users. Addict Behav. 2010;35(1):23–29.
24.
WareJJr., KosinskiM, KellerSD.A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233.
25.
DelateT, CoonsSJ.The discriminative ability of the 12-item short form health survey (SF-12) in a sample of persons infected with HIV. Clin Ther.2000;22(9):1112–1120.
26.
SherbourneCD, StewartAL.The MOS social support survey. Soc Sci Med. 1991;32(6):705–714.
27.
SaundersJB, AaslandOG, BaborTF, De La FuenteJR, GrantM.Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction. 1993;88(6):791–804.
SpringerSA, BrownSE, Di PaolaA, AlticeFL.Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend. 2015;157:158–165.
30.
GryczynskiJ, MitchellSG, JaffeJH, O'GradyKE, OlsenYK, SchwartzRP.Leaving buprenorphine treatment: patients’ reasons for cessation of care. J Subst Abuse Treat. 2014;46(3):356–361.
31.
SullivanLE, MooreBA, O'ConnorPG, . The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am J Addict.2010;19(1):53–58.
32.
LeskoCR, KeilAP, FojoAT, ChanderG, LauB, MooreRD.Recent substance use and probability of unsuppressed HIV viral load among persons on antiretroviral therapy in continuity care. Am J Epidemiol. 2019;188(10):1830–1837.
33.
IrohPA, MayoH, NijhawanAE.The HIV care cascade before, during, and after incarceration: a systematic review and data synthesis. Am J Public Health. 2015;105(7):e5–e16.
34.
ChitsazE, MeyerJP, KrishnanA, . Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. AIDS Behav. 2013;17(Suppl 2):S118–S27.
35.
CohenMH, CookJA, GreyD, . Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health. 2004;94(7):1147–1151.
36.
LichtensteinB.Domestic violence in barriers to health care for HIV-positive women. AIDS Patient Care Stds. 2006;20(2):122–132.
37.
FlowerSM.Employment and Female Offenders: An Update of the Empirical Research. Washington, DC: U.S. Department of Justice, National Institute of Corrections; 2010.
38.
RabkinJG, JohnsonJ, LinSH, . Psychopathology in male and female HIV-positive and negative injecting drug users: longitudinal course over 3 years. AIDS. 1997;11(4):507–515.
39.
BengtsonAM, PenceBW, CraneHM, . Disparities in depressive symptoms and antidepressant treatment by gender and race/ethnicity among people living with HIV in the United States. PloS One .2016;11(8):e0160738.
40.
MbabaM, BrownSE, WooditchA, . Prevalence, diagnosis, and treatment rates of mood disorders among opioid users under criminal justice supervision. Subst Use Misuse. 2018;53(9):1519–1528.
41.
Di PaolaA, AlticeFL, PowellML, TrestmanRL, SpringerSA.A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community. Health Justice. 2014;2(1):11.
42.
BerenzEC, Roberson-NayR, LatendresseSJ, . Posttraumatic stress disorder and alcohol dependence: epidemiology and order of onset. Psychol Trauma. 2017;9(4):485–492.
43.
MachtingerEL, WilsonTC, HabererJE, WeissDS.Psychological trauma and PTSD in HIV-positive women: a meta-analysis. AIDS Behav. 2012;16(8):2091–2100.
44.
DanskyBS, SaladinME, BradyKT, KilpatrickDG, ResnickHS.Prevalence of victimization and posttraumatic stress disorder among women with substance use disorders: comparison of telephone and in-person assessment samples. Int J Addict. 1995;30(9):1079–1099.
45.
BarryDT, PilverC, PotenzaMN, DesaiRA.Prevalence and psychiatric correlates of pain interference among men and women in the general population. J Psychiatr Res.2012;46(1):118–127.
46.
RisserJ, CatesA, RehmanH, RisserW.Gender differences in social support and depression among injection drug users in Houston, Texas. Am J Drug Alcohol Abuse. 2010;36(1):18–24.
